To get multi agonists based on GLP-1, 15 conjugates were designed, synthesized, and tested for biological activity. GLP-1/glucagon dual receptor agonist E1 showed moderate long-acting hypoglycemic effect, CY-5 and CY-16 with GLP-1/GIP dual receptor agonistic activity exhibited longer duration ...
HRS9531作为GLP-1/GIP双受体激动剂,激活GIP受体和GLP-1受体信号通路,通过对胰岛β细胞的双重作用来增强胰岛素分泌,对大脑两种受体信号通路的激活产生更强烈的抑制食欲作用,同时GIP发挥对脂肪存储和脂肪组织功能的重要调控作用,表现为增加白...
3. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonist. Front Endocrinol, 2024, 15: 1431292. 4. Informa数据库, 检索日期: 2024年11月15日. 5. 药渡数据库, 检索日期: 2024年11月15日. 6. 药明...
4.Zhao L, et al. 1861-LB#Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Obese Adults: A Phase 2 Trial. Presented at ADA 2024.
me/src/EventPilot/php/express/web/page.php?page=IntHtml&project=ADA23&id=789.3. Zhao J, et al.LBA 66Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist, in patients with type 2 diabetes mellitus (T2DM): a phase 2 trial. Presented at EASD annual meeting.
Description:DA-JC4 是一种双GLP-1/GIP receptor激动剂多肽,序列中含有45个氨基酸,可用于神经系统疾病和胰岛素信号通路的研究。 DA-JC4 is a dual GLP-1/GIP receptor agonist peptide with a sequence containing 45 amino acids, which can be used for research on neurological diseases and insulin signaling...
Tirzepatide is a novel once-weekly dual GIP and GLP-1 receptor agonist which has shown to be safe and effective in treating type 2 diabetes. Significant A1C reduction and weight loss was demonstrated across all doses. Most adverse events were gastrointestinal in nature. Declaration of competing...
There’s also a similar class of medications calleddualGLP-1/GIP receptor agonists. There’s currently one of these medications on the market. It’s calledtirzepatide(Mounjaro®). dual :双重的 How do GLP-1 agonists work? To understand how GLP-1 agonists work, it helps to understand how...
1. Zhao L, et al. 1861-LB#Efficacy and Safety of HRS9531, a Novel Dual GLP-1/GIP Receptor Agonist, in Obese Adults: A Phase 2 Trial. Presented at ADA 2024. 2. Nauck, et al. Lancet Diabetes Endocrinol.2016; 4: 525-36.
1. 吴霞, 等. 中华糖尿病杂志. 2022; 14(11): 1321-1326. 2.网页链接 3. Zhao J, et al.LBA 66Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist, in patients with type 2 diabetes mellitus (T2DM): a phase 2 trial. Presented at EASD annual meeting. ...